Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice

Naoichiro Hattan, Haruko Kawaguchi, Kiyoshi Ando, Eriko Kuwabara, Jun Fujita, Mitsushige Murata, Makoto Suematsu, Hidezo Mori, Keiichi Fukuda

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

We have previously isolated cardiomyogenic cells from murine bone marrow (CMG cells). Regenerated cardiomyocytes are important candidates for cell transplantation, but as they are stem cell derived, they can be contaminated with various cell types, thereby requiring characterization and purification. Our objectives were to increase the efficiency of cell transplantation and to protect the recipients from possible adverse effects using an efficient and effective purification process as well as to characterize regenerated cardiomyocytes. Noncardiomyocytes were eliminated from a mixture of stem-cell-derived cells using a fluorescence-activated cell sorter to specifically isolate CMG cells transfected with a recombinant plasmid containing enhanced green fluorescent protein (EGFP) cDNA under the control of the myosin light chain-2v (MLC-2v) promoter. Gene expression and the action potential were investigated, and purified cells were transplanted into the heart of adult mice. Six percent to 24% of transfected CMG cells expressed EGFP after differentiation was induced, and a strong EGFP-positive fraction was selected. All the sorted cells began spontaneous beating after 3 weeks. These cells expressed cardiomyocyte-specific genes such as α-skeletal actin, β-myosin heavy chain, MLC-2v, and CaV1.2 and incorporated bromodeoxyuridine for 5 days. The isolated EGFP-positive cells were expanded for 5 days and then transplanted into the left ventricle of adult mouse hearts. The transplanted cells survived for at least 3 months and were oriented in parallel to the cardiomyocytes of the recipient heart. The purification and transplantation of differentiated cardiomyocytes from adult stem cells provides a viable model of tissue engineering for the treatment of heart failure.

Original languageEnglish
Pages (from-to)334-344
Number of pages11
JournalCardiovascular Research
Volume65
Issue number2
DOIs
Publication statusPublished - 2005 Feb 1

Fingerprint

Mesenchymal Stromal Cells
Cardiac Myocytes
Bone Marrow
Transplants
Myosin Light Chains
Stem Cell Transplantation
Adult Stem Cells
Myosin Heavy Chains
Cell Transplantation
Bromodeoxyuridine
Tissue Engineering
Treatment Failure
Bone Marrow Cells
Action Potentials
Heart Ventricles
Actins
Plasmids
Stem Cells
Heart Failure
Complementary DNA

Keywords

  • Bone marrow
  • Cardiomyocytes
  • Heart failure
  • Stem cell
  • Transplantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice. / Hattan, Naoichiro; Kawaguchi, Haruko; Ando, Kiyoshi; Kuwabara, Eriko; Fujita, Jun; Murata, Mitsushige; Suematsu, Makoto; Mori, Hidezo; Fukuda, Keiichi.

In: Cardiovascular Research, Vol. 65, No. 2, 01.02.2005, p. 334-344.

Research output: Contribution to journalArticle

Hattan, N, Kawaguchi, H, Ando, K, Kuwabara, E, Fujita, J, Murata, M, Suematsu, M, Mori, H & Fukuda, K 2005, 'Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice', Cardiovascular Research, vol. 65, no. 2, pp. 334-344. https://doi.org/10.1016/j.cardiores.2004.10.004
Hattan, Naoichiro ; Kawaguchi, Haruko ; Ando, Kiyoshi ; Kuwabara, Eriko ; Fujita, Jun ; Murata, Mitsushige ; Suematsu, Makoto ; Mori, Hidezo ; Fukuda, Keiichi. / Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice. In: Cardiovascular Research. 2005 ; Vol. 65, No. 2. pp. 334-344.
@article{982fb20060e448c8a6facdcb09516033,
title = "Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice",
abstract = "We have previously isolated cardiomyogenic cells from murine bone marrow (CMG cells). Regenerated cardiomyocytes are important candidates for cell transplantation, but as they are stem cell derived, they can be contaminated with various cell types, thereby requiring characterization and purification. Our objectives were to increase the efficiency of cell transplantation and to protect the recipients from possible adverse effects using an efficient and effective purification process as well as to characterize regenerated cardiomyocytes. Noncardiomyocytes were eliminated from a mixture of stem-cell-derived cells using a fluorescence-activated cell sorter to specifically isolate CMG cells transfected with a recombinant plasmid containing enhanced green fluorescent protein (EGFP) cDNA under the control of the myosin light chain-2v (MLC-2v) promoter. Gene expression and the action potential were investigated, and purified cells were transplanted into the heart of adult mice. Six percent to 24{\%} of transfected CMG cells expressed EGFP after differentiation was induced, and a strong EGFP-positive fraction was selected. All the sorted cells began spontaneous beating after 3 weeks. These cells expressed cardiomyocyte-specific genes such as α-skeletal actin, β-myosin heavy chain, MLC-2v, and CaV1.2 and incorporated bromodeoxyuridine for 5 days. The isolated EGFP-positive cells were expanded for 5 days and then transplanted into the left ventricle of adult mouse hearts. The transplanted cells survived for at least 3 months and were oriented in parallel to the cardiomyocytes of the recipient heart. The purification and transplantation of differentiated cardiomyocytes from adult stem cells provides a viable model of tissue engineering for the treatment of heart failure.",
keywords = "Bone marrow, Cardiomyocytes, Heart failure, Stem cell, Transplantation",
author = "Naoichiro Hattan and Haruko Kawaguchi and Kiyoshi Ando and Eriko Kuwabara and Jun Fujita and Mitsushige Murata and Makoto Suematsu and Hidezo Mori and Keiichi Fukuda",
year = "2005",
month = "2",
day = "1",
doi = "10.1016/j.cardiores.2004.10.004",
language = "English",
volume = "65",
pages = "334--344",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice

AU - Hattan, Naoichiro

AU - Kawaguchi, Haruko

AU - Ando, Kiyoshi

AU - Kuwabara, Eriko

AU - Fujita, Jun

AU - Murata, Mitsushige

AU - Suematsu, Makoto

AU - Mori, Hidezo

AU - Fukuda, Keiichi

PY - 2005/2/1

Y1 - 2005/2/1

N2 - We have previously isolated cardiomyogenic cells from murine bone marrow (CMG cells). Regenerated cardiomyocytes are important candidates for cell transplantation, but as they are stem cell derived, they can be contaminated with various cell types, thereby requiring characterization and purification. Our objectives were to increase the efficiency of cell transplantation and to protect the recipients from possible adverse effects using an efficient and effective purification process as well as to characterize regenerated cardiomyocytes. Noncardiomyocytes were eliminated from a mixture of stem-cell-derived cells using a fluorescence-activated cell sorter to specifically isolate CMG cells transfected with a recombinant plasmid containing enhanced green fluorescent protein (EGFP) cDNA under the control of the myosin light chain-2v (MLC-2v) promoter. Gene expression and the action potential were investigated, and purified cells were transplanted into the heart of adult mice. Six percent to 24% of transfected CMG cells expressed EGFP after differentiation was induced, and a strong EGFP-positive fraction was selected. All the sorted cells began spontaneous beating after 3 weeks. These cells expressed cardiomyocyte-specific genes such as α-skeletal actin, β-myosin heavy chain, MLC-2v, and CaV1.2 and incorporated bromodeoxyuridine for 5 days. The isolated EGFP-positive cells were expanded for 5 days and then transplanted into the left ventricle of adult mouse hearts. The transplanted cells survived for at least 3 months and were oriented in parallel to the cardiomyocytes of the recipient heart. The purification and transplantation of differentiated cardiomyocytes from adult stem cells provides a viable model of tissue engineering for the treatment of heart failure.

AB - We have previously isolated cardiomyogenic cells from murine bone marrow (CMG cells). Regenerated cardiomyocytes are important candidates for cell transplantation, but as they are stem cell derived, they can be contaminated with various cell types, thereby requiring characterization and purification. Our objectives were to increase the efficiency of cell transplantation and to protect the recipients from possible adverse effects using an efficient and effective purification process as well as to characterize regenerated cardiomyocytes. Noncardiomyocytes were eliminated from a mixture of stem-cell-derived cells using a fluorescence-activated cell sorter to specifically isolate CMG cells transfected with a recombinant plasmid containing enhanced green fluorescent protein (EGFP) cDNA under the control of the myosin light chain-2v (MLC-2v) promoter. Gene expression and the action potential were investigated, and purified cells were transplanted into the heart of adult mice. Six percent to 24% of transfected CMG cells expressed EGFP after differentiation was induced, and a strong EGFP-positive fraction was selected. All the sorted cells began spontaneous beating after 3 weeks. These cells expressed cardiomyocyte-specific genes such as α-skeletal actin, β-myosin heavy chain, MLC-2v, and CaV1.2 and incorporated bromodeoxyuridine for 5 days. The isolated EGFP-positive cells were expanded for 5 days and then transplanted into the left ventricle of adult mouse hearts. The transplanted cells survived for at least 3 months and were oriented in parallel to the cardiomyocytes of the recipient heart. The purification and transplantation of differentiated cardiomyocytes from adult stem cells provides a viable model of tissue engineering for the treatment of heart failure.

KW - Bone marrow

KW - Cardiomyocytes

KW - Heart failure

KW - Stem cell

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=11444270758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11444270758&partnerID=8YFLogxK

U2 - 10.1016/j.cardiores.2004.10.004

DO - 10.1016/j.cardiores.2004.10.004

M3 - Article

C2 - 15639472

AN - SCOPUS:11444270758

VL - 65

SP - 334

EP - 344

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 2

ER -